Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POD1UM-101: Retifanlimab in Advanced Solid Tumors
NCT03059823Phase 1Completed
- Sponsor
- Incyte
- Start
- Nov 2016
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 1, open-label trial of retifanlimab in solid tumor, endometrial cancer (EC), Cervical Cancer (CC) and 2 more (4 arms), sponsored by Incyte. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 24 months and Maximum Tolerated Dose at 24 months. Started Nov 2016; status: completed.
02
Drugs
retifanlimab
03
Conditions
solid tumorendometrial cancer (EC)Cervical Cancer (CC)sarcomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03059823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03059823.